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Abstract
Background: Mediterranean spotted fever (MSF) is an acute febrile, zoonotic disease caused by
Rickettsia conorii and transmitted to humans by the brown dogtick Rhipicephalus sanguineus. Nearly
four hundred cases are reported every year (mainly from June to September) on the Italian island
of Sicily. The aim of the study was to analyze the clinical and laboratory characteristics of patients
with MSF and the efficacy of the drugs administered.
Methods: Our study was carried out on 415 children with MSF, during the period January 1997 –
December 2004, at the "G. Di Cristina" Children's hospital in Palermo, Sicily, Italy. On admission
patients' clinical history, physical and laboratory examination and indirect immunofluorescence
antibody test (IFAT) for Rickettsia conorii were performed. Diagnosis was considered confirmed if
the patients had an MSF diagnostic score greater than or equal to 25 according to the Raoult's
scoring system. All patients were treated with chloramphenicol or with macrolides (clarithromycin
or azithromycin).
Results: Fever, rash and tache noire were present in 386 (93%), 392 (94.5%) and 263 (63.4%) cases
respectively. Eighteen (4.6%) children showed atypical exanthema. Chloramphenicol and newer
macrolides all appeared to be effective and safe therapies.
Conclusion: Clinical features of 415 children with MSF were similar to those reported by other
authors except for a lower incidence of headache, arthralgia and myalgia and a higher frequency of
epato-splenomegaly. Concerning therapy, clarithromycin can be considered a valid alternative
therapy to tetracyclines or chloramphenicol especially for children aged < eight years.
Background
Mediterranean spotted fever (MSF) is an acute febrile,
zoonotic disease caused by Rickettsia conorii and transmit-
ted to humans by the brown dog tick Rhipicephalus san-
guineus, which is generally considered to be the most
common tick in the Mediterranean area. Nearly four hun-
dred cases are reported every year (mainly from June to
September) on the Italian island of Sicily [1]. Interest-
ingly, the number of cases in Italy and elsewhere appears
to have increased over the past 20 years. Sporadic cases
have also been diagnosed in travelers to other countries,
and, in North America, MSF is one of the most frequently
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imported types of rickettsioses [2]. Until recently Rickettsia
conorii  was thought to be the main species in Europe.
However, in the last decade newly recognized tick-borne
rickettsioses have been shown to be prevalent in Europe;
in 1996 and 1997, the first documented cases of infection
due to Rickettsia mongolotimonae and  Rickettsia slovaca
respectively, were reported in France [3,4]. More recently
Rickettsia helvetica has been identified in Sweden and
France [5,6] and Rickettsia Israeli in Sicily and Portugal
[7,8]. In Sicily two subspecies of Rickettsia conorii has
been found: Rickettsia conorii conorii and Rickettsia Israeli
[9]. MSF is typically characterized by fever, skin rash and
a black eschar at the site of the tick bite ("tache noire")
[10]. Actually more and more frequently severe forms are
described and the current fatality rate of MSF is increasing
[11]. Diagnosis is based on epidemiological, clinical and
laboratory criteria [12]. Serological confirmation of infec-
tion is obtained using indirect immunofluorescence
against Rickettsia conorii. Promptly administered antibiotic
treatment shortens the symptomatic period of MSF infec-
tion and prevents the appearance of severe complications.
Over the last few years the new macrolides have been
widely employed and have became the antibiotic of
choice for treating pediatric MSF [13,14].
The objective of this study was to analyze the clinical and
laboratory characteristics of patients diagnosed with MSF
at our hospital over the last eight years and to analyze the
efficacy of the drugs administered.
Methods
All patients diagnosed with MSF at the "G. Di Cristina"
Children's hospital in Palermo, Italy, during the period
January 1997 – December 2004, were included in this
case series. Clinical suspicion of MSF was based on a his-
tory of a tick bite or direct contact with dogs, and on the
presence of fever, non confluent maculopapular rash,
tache noire, lymphadenopathy. On admission, a com-
plete physical and laboratory examination (complete
blood cell count, kidney and liver function tests, determi-
nation of the erythrocyte sedimentation rate, urine analy-
sis) was carried out on most children. An indirect
immunofluorescence assay for Rickettsia conorii was per-
formed using a commercial kit (Rickettsia conorii-Spot;
bio-Merieux, Marcy l'Etoile, France) when the first blood
sample was taken and then, again, two weeks later (acute
and convalescent-phase serum samples). Diagnosis was
considered confirmed if the patients had an MSF diagnos-
tic score of ≥ 25 according to the scoring system described
in Raoult et al. [12].
All patients were treated with chloramphenicol or with
macrolides. Chloramphenicol, administered orally or
intravenously at a dosage of 50 mg/Kg/day in four divided
doses for 7 days, was the first choice therapy until 1999.
Since 2000, clarithromycin or azithromycin have been
administered orally at a dosage of 15 mg/Kg/day in two
divided doses for 7 days and 10 mg/Kg once daily for 3
days, respectively. Intravenously administered chloram-
phenicol was used for patients suffering from allergy,
those having side effects (vomiting or profuse diarrhea),
fever that persisted for > 5 days or relapse after therapy
with macrolides. Antibiotic treatment prompted a clinical
response in the shape of defervescence and an improve-
ment in the clinical profile. Defervescence time was
defined as the period from when antibiotic treatment
began to the moment when defervescence first became
constant (i.e. an axillary body temperature of ≤ 37°C for
at least 3 consecutive days). Relapse was defined as the
reappearance of fever within a week after the end of ther-
apy.
Statistical analysis
Analysis was carried out using the parametric ANOVA test
for continuous factors; simultaneous comparisons of sev-
eral proportions were performed using chi square test.
Results
A total of 415 patients were diagnosed with Rickettsia
conorii infection during the study period. The annual inci-
dence of MSF infection ranged from 29 cases in 2004 to
98 in 1999. Most of the cases (n = 334) occurred between
July and September, one case occurred in December. The
median age was 6 years (range: 1 month-15 years). Two-
hundred and forty-five (59%) of the children were male.
A history of a tick-bite was given in 142 (34.2%) cases.
Direct contact with dogs was reported in 86 (20.7%)
cases. Patients were seen to in the emergency department
after a median of 3 days (range 1–9) of fever. Table 1
shows the main clinical characteristics of the 415 cases.
With regard to exanthema it was observed in 392 (94.5%)
patients and was typical (maculopapular spreading to the
Table 1: Clinical findings in 415 children with Mediterranean 
spotted fever.
Clinical manifestations No. (%) of cases
Fever 386 (93)
Rash 392 (94.5)
Tache noire 263 (63.4)
Local lymphoadenopathy 214 (51.6)
Headache 122 (29.4)
Arthralgia and myalgia 158 (38.1)
Arthritis 3 (0.7)
Gastrointestinal symptoms 116 (27.9)
Hepatomegaly and/or splenomegaly 273 (65.8)
Orchitis 1 (0.2)
Conjunctival hyperaemia 53 (12.8)
Meningism 3 (0.7)
Meningitis 1 (0.2)BMC Infectious Diseases 2006, 6:60 http://www.biomedcentral.com/1471-2334/6/60
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palm and soles) in 374 (95.4%) of the cases and atypical
in 18 cases (4.6%). Among atypical exanthema, petechial
or purpuric rash was observed in nine cases (2.3%), papu-
lovesicular in eight (2%), both purpuric and vesicular in
one case (0.2%). Two hundred and thirty six patients pre-
sented exanthema, fever and tache noire together. Among
23 (5.5%) children without exanthema, 14 had fever,
tache noire and lymphadenopathy, 2 fever and tache
noire, 2 tache noire and lymphadenopathy, 2 only tache
noire, 1 fever and lymphadenopathy, 1 fever and at last 1
headache and vomiting. In all tache noire was observed in
63.4% patients; it was a solitary lesion in 257 patients,
while six patients presented two or three lesions.
Arthralgia and/or mialgia generally affected the joints and
the muscles of the lower limbs and only in three (0.7%)
cases restricted children's mobility. One girl aged 14 years
developed meningo-encephalitis.
As regards haematological parameters, leucopenia (≤
5,000/mm3) was found in 114 (27.5%) patients, leucocy-
tosis (≥ 10,000/mm3) in 46 (11.1%), thrombocytopenia
(< 150,000/mm3) in 54 (13%) cases, thrombocytosis (>
400,000/mm3) in nine (2.2%) cases. AST and/or ALT level
were abnormal (>50 IU/ml) in 87 (21%) cases. In one
patient ALT was 489 IU/l and no other infection was doc-
umented. Urine analysis, performed in 212 patients,
revealed erythrocyturia in 145 (68.4%) and proteinuria in
105 (49.5%) cases.
Indirect immunofluorescence to Rickettsia conorii was per-
formed in 365 (87.9%) cases. Serological confirmation of
infection was obtained for 232 (63.6%) patients; 154
patients had diagnostic antibody titre on admission,
while 78 showed a 4-fold titre elevation after two weeks.
Among 133 cases not serologically confirmed, 124
patients had negative serology on admission and did not
came back after two weeks; in nine cases with negative
serology both on admission and in convalescence the
diagnosis has been made on the grounds of clinical and
epidemiologic criteria.
With regard to therapy, chloramphenicol was used from
the beginning in 107 children (87 orally and 20 intrave-
nously); 230 children were given clarithromycin, 78 azi-
thromycin. All drugs were well tolerated, without
evidence of toxicity or major side-effects. Twenty-eight
patients initially treated with macrolides had to change
therapy to i.v. chloramphenicol because of occurrence of
vomiting and/or diarrhoea (15 patients treated with clari-
thromycin and one treated with azithromycin), itching
rash (one patient treated with clarithromycin), fever that
persisted for > 5 days (two patients treated with clarithro-
mycin and nine treated with azithromycin). A further 19
patients treated with clarithromycin developed irrelevant
side effects which did not require discontinuation of ther-
apy.
Defervescence time and the mean duration of hospitaliza-
tion in the three different groups of treatment are shown
in table 2. There was no difference in the defervescence
time (p = 0.093); in contrast, hospitalization was signifi-
cantly longer in the chloramphenicol group compared
with clarithromycin group (p = 0.018). The course of the
disease was favourable in all cases.
Discussion
MSF is an acute disease caused by Rickettsia conorii, which
is transmitted to humans by the brown dog-tick Rhipiceph-
alus sanguineus. Ticks are not only vectors, but also reser-
voirs of Rickettsia so that physical contact with dogs is not
necessary. In fact in our case series only a few patients
(20.7%) presented this risk factor.
In our area the disease affects individuals of both sexes
and all ages, and, in contrast to what was reported by
Anton et al. [15], no peak is found in the pediatric popu-
lation [1].
Comparing the results of our study with previous ones, we
found clinical features similar to those reported by other
authors except for a lower incidence of headache, arthral-
gia and myalgia and a higher frequency of hepato-
splenomegaly (table 1) [10,15-17]. Headache is one of
the typical and more discomforting symptoms of the dis-
ease in adults [15] and its lower frequency in children cer-
tainly contributes to the milder clinical presentation in
this age group.
In the last decade newly recognized tick-borne rickettsi-
oses have been shown to be prevalent in Europe. In 1997
Rickettsia slovaca, transmitted by the Dermacentor margina-
tus tick was linked to the illness occurring especially in
children < 10 years, during the autumn and winter and
characterized by scalp lesions due to tick-bites and
enlarged regional lymph nodes. This clinical syndrome
was denominated TIBOLA (tick-borne lymphadenopa-
thy) [18]. In our case series, eight patients with tache noire
in the scalp and lymphadenopathy, six of them also show-
ing fever, could fit the diagnosis of TIBOLA. Because of the
scarce specificity of standard serological methods [18] we
are not be able to make a definitive diagnosis that could
be made using isolation or molecular biology to establish
and clearly identify agents.
Severe involvement of the central nervous system has
been reported in adults with Rickettsia conorii infection
[19-22], but is extremely rare in children [23-25]. We
report a case of meningoencephalitis in a 14-yearold girl.
The patient came to our notice after nine days of highBMC Infectious Diseases 2006, 6:60 http://www.biomedcentral.com/1471-2334/6/60
Page 4 of 5
(page number not for citation purposes)
fever, headache, arthralgia with no history of tick-bite. On
clinical observation there was no evidence of tache noire
and only a few maculopapular elements, involving nei-
ther the palms nor the soles, were present. The patient had
a severely-affected central nervous system with obtunded
consciousness, facial nerve deficit and meningeal signs.
Examination of cerebrospinal fluid did not reveal any sig-
nificant findings. Magnetic resonance imaging of the
brain showed contrast enhancement in the meninges.
Indirect immunofluorescence to Rickettsia conorii was pos-
itive on admission and showed a 4-fold titre elevation
after two weeks. Intravenous administration of chloram-
phenicol for 15 days led to the disappearance of symp-
toms.
Standard treatment for MSF has been tetracyclines or chlo-
ramphenicol [26]. According to the American Academy of
Pediatrics tetracyclines are not indicated for the treatment
of common infections in children younger than eight
years of age. However doxycycline is recommended for
treatment of Rocky Mountain spotted fever in children of
any age [27]. The milder clinical presentation and the
benign course of MSF allow us to utilize macrolides,
which are often used to treat infections in children, that
lack adverse effects and are effective in vitro against Rickett-
sia conorii [28-30].
Several randomized clinical trials have been performed to
compare macrolides in the treatment of MSF [31-33].
More recently good in vivo results were obtained for the
new macrolides, identifying clarithromycin as a valid
alternative therapy to tetracyclines or chloramphenicol for
children aged < eight years [13,14].
In our case series there were no differences in the three
groups of treatment with regard to the defervescence time
(p = 0.093); the incidence of relapses and of side effects
requiring a change of therapy was quite low, even if signif-
icantly different for the three drugs (p < 0.01). On the
other hand, the shorter hospitalization stay in the clari-
thromycin group (p = 0.018), good compliance observed
both in patients treated with clarithromycin and azithro-
mycin, together with the withdrawal of oral formulation
of chloramphenicol, confirm the leading role of clarithro-
mycin in the treatment of pediatric MSF.
Conclusion
As already known, MSF confirms to be an acute disease
with a benign course in pediatric age. Nevertheless spo-
radic severe clinical manifestation can be observed. Com-
plete evaluation of epidemiological, clinical and
serological criteria is necessary to establish a prompt diag-
nosis and safe therapy. Clarithromycin and azithromycin,
because of the lack of adverse effects and a good compli-
ance, can be considered a valid alternative therapy to tet-
racyclines or chloramphenicol in the treatment of
pediatric MSF especially for children aged < eight years.
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